Gan & Lee Pharmaceuticals

📍 Tongzhou District, China🗓 Founded 1998👥 454 employees💰 Last funded 2009
Pharmaceutical Manufacturing🌐 ganlee.com
Website LinkedIn
Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1998
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
1
Frequently asked questions
Who invested in Gan & Lee Pharmaceuticals?
Gan & Lee Pharmaceuticals has 1 investors on record on gritt.io.
When did Gan & Lee Pharmaceuticals last raise funding?
The most recent investment in Gan & Lee Pharmaceuticals recorded on gritt.io was in 2009.
When was Gan & Lee Pharmaceuticals founded?
Gan & Lee Pharmaceuticals was founded in 1998.
What industry is Gan & Lee Pharmaceuticals in?
Gan & Lee Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Gan & Lee Pharmaceuticals based?
Gan & Lee Pharmaceuticals is headquartered in Tongzhou District, China.